TipRanks
Go Ultimate55% OFF

Compare GlaxoSmithKline (GS71) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:GS71GlaxoSmithKlineEUR 21.88EUR 89.12B17.187.68%NeutralUnlock the DE:GS71 analyst price target with TipRanks PremiumDE:GS71Unlock the DE:GS71 top-analyst price target with TipRanks Premium
GB:AZNAstraZenecaGBX 13,832.00GBX 216.51B26.2711.15%Strong BuyUnlock the GB:AZN analyst price target with TipRanks PremiumDE:GS71 vs GB:AZNUnlock the GB:AZN top-analyst price target with TipRanks Premium
GB:HIKHikma PharmaceuticalsGBX 1,755.00GBX 3.58B12.95-4.95%Strong BuyUnlock the GB:HIK analyst price target with TipRanks PremiumDE:GS71 vs GB:HIKUnlock the GB:HIK top-analyst price target with TipRanks Premium
GB:SNSmith & NephewGBX 1,108.00GBX 9.27B19.52-21.35%NeutralUnlock the GB:SN analyst price target with TipRanks PremiumDE:GS71 vs GB:SNUnlock the GB:SN top-analyst price target with TipRanks Premium
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegSGBX 55.13GBX 64.11B4.6825.58%―Unlock the GB:BXP analyst price target with TipRanks PremiumDE:GS71 vs GB:BXPUnlock the GB:BXP top-analyst price target with TipRanks Premium
GB:HLNHaleon PLCGBX 322.20GBX 28.09B17.61-8.73%Moderate BuyUnlock the GB:HLN analyst price target with TipRanks PremiumDE:GS71 vs GB:HLNUnlock the GB:HLN top-analyst price target with TipRanks Premium

Performance Comparison

-40%-20%0%20%40%60%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:GS71GlaxoSmithKline21.881.788.86%
GB:AZNAstraZeneca13860.001703.7114.02%
GB:HIKHikma Pharmaceuticals1748.008.150.47%
GB:SNSmith & Nephew1105.00-254.38-18.71%
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegS54.0012.9231.44%
GB:HLNHaleon PLC323.20-27.40-7.81%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts